EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HLA Variation and SARS-CoV-2 Specific Antibody Response

Dawit Wolday, Chun Yiu Jordan Fung, Gregory Morgan iD, Selina Casalino, Erika Frangione, Jennifer Taher iD, Jordan P Lerner-Ellis iD

Viruses · 2023

DOI: 10.3390/v15040906 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Dawit Wolday und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1Z5, Canada. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Differences in SARS-CoV-2-specific immune responses have been observed between individuals following natural infection or vaccination. In addition to already known factors, such as age, sex, COVID-19 severity, comorbidity, vaccination status, hybrid immunity, and duration of infection, inter-individual variations in SARS-CoV-2 immune responses may, in part, be explained by structural differences brought about by genetic variation in the human leukocyte antigen (HLA) molecules responsible for the presentation of SARS-CoV-2 antigens to T effector cells. While dendritic cells present peptides with HLA class I molecules to CD8+ T cells to induce cytotoxic T lymphocyte responses (CTLs), they present peptides with HLA class II molecules to T follicular helper cells to induce B cell differentiation followed by memory B cell and plasma cell maturation. Plasma cells then produce SARS-CoV-2-specific antibodies. Here, we review published data linking HLA genetic variation or polymorphisms with differences in SARS-CoV-2-specific antibody responses. While there is evidence that heterogeneity in antibody response might be related to HLA variation, there are conflicting findings due in part to differences in study designs. We provide insight into why more research is needed in this area. Elucidating the genetic basis of variability in the SARS-CoV-2 immune response will help to optimize diagnostic tools and lead to the development of new vaccines and therapeutics against SARS-CoV-2 and other infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAntibody FormationHistocompatibility Antigens Class IHLA AntigensHistocompatibility AntigensCD8-Positive T-LymphocytesPeptidesHistocompatibility Antigens Class II

Stichwörter der Autor:innen

COVID-19HLAMHCSARS-CoV-2antibodygenomicsimmunoglobulinpolymorphism

Substanzen

Histocompatibility Antigens Class IHLA AntigensHistocompatibility AntigensPeptidesHistocompatibility Antigens Class II

Autor:innen und Institutionen

  • Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1Z5, Canada.
  • Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G 1Z5, Canada.

ORCID-Profile: Gregory Morgan, Jennifer Taher, Jordan P Lerner-Ellis

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Wolday, D., Fung, C. Y. J., Morgan, G., Casalino, S., Frangione, E., Taher, J., & Lerner-Ellis, J. P. (2023). HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses. https://doi.org/10.3390/v15040906

Vancouver

Wolday D, Fung CYJ, Morgan G, Casalino S, Frangione E, Taher J, et al. HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses. 2023. doi:10.3390/v15040906

BibTeX
@article{Wolday2023,
  author = {Wolday, Dawit and Fung, Chun Yiu Jordan and Morgan, Gregory and Casalino, Selina and Frangione, Erika and Taher, Jennifer and Lerner-Ellis, Jordan P},
  title = {HLA Variation and SARS-CoV-2 Specific Antibody Response},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15040906}
}
Kostenlos starten →